Immunohistochemistry as a screening tool for ALK rearrangement in NSCLC: Evaluation of five different ALK antibody clones and ALK FISH

Histopathology

Volumn 65, Issue 3, 2014, Pages 398-407

  Hutarew, Georg ^a   Hauser Kronberger, Cornelia ^a   Strasser, Felix ^a   Llenos, Ida C ^a   Dietze, Otto ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

ALK antibody clones; ALK FISH; ALK mutations in non small cell lung cancer; EML4 ALK rearrangement; Immunohistochemical screening for ALK rearrangements

Indexed keywords

5A4 PROTEIN; ACTIVIN RECEPTOR LIKE KINASE 1; ALK01 PROTEIN; D5F3 PROTIEN; PROTEIN TYROSINE KINASE; SP8 PROTEIN; UNCLASSIFIED DRUG; ANAPLASTIC LYMPHOMA KINASE; MONOCLONAL ANTIBODY;

ADULT; ANTIBODY SCREENING; ARTICLE; CANCER SCREENING; CLINICAL EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR CLONING; PRIORITY JOURNAL; ADENOCARCINOMA; AGED; ANIMAL; DIAGNOSTIC USE; ENZYMOLOGY; EVALUATION STUDY; GENETICS; IMMUNOLOGY; LUNG TUMOR; METABOLISM; MIDDLE AGED; MOUSE; MUTATION; NON SMALL CELL LUNG CANCER; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; RABBIT;

ADENOCARCINOMA; ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; RABBITS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84920523851     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12399     Document Type: Article

References (38)

1. Park HS, Lee JK, Kim DW et al. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. Lung Cancer 2012; 77; 288-292.
2. Koivunen JP, Mermel C, Zejnullahu K et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008; 14; 4275-4283.
3. Takeuchi K, Choi YL, Soda M et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin. Cancer Res. 2008; 14; 6618-6624.
4. Inamura K, Takeuchi K, Togashi Y et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod. Pathol. 2009; 22; 508-515.
5. Wong DW, Leung EL, So KK et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009; 115; 1723-1733.
6. Ramalingam SS, Owonikoko TK, Khuri FR. Lung cancer: new biological insights and recent therapeutic advances. CA Cancer J. Clin. 2011; 61; 91-112.
7. Zhong S, Zhang HP, Zheng J, Bai DY, Fu L, Chen PQ. Detection of EML4-ALK fusion gene in non-small cell lung cancer and its clinicopathologic correlation. Zhonghua Bing Li Xue Za Zhi 2013; 42; 252-256.
8. Yip PY, Yu B, Cooper WA et al. Patterns of DNA mutations and ALK rearrangement in resected node negative lung adenocarcinoma. J. Thorac. Oncol. 2013; 8; 408-414.
9. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448; 561-566.
10. Roskoski R Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition. Pharmacol. Res. 2013; 68; 68-94.
11. Choi YL, Takeuchi K, Soda M et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res. 2008; 68; 4971-4976.
12. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J. Clin. Oncol. 2009; 27; 4232-4235.
13. Arai Y, Totoki Y, Takahashi H et al. Mouse model for ROS1-rearranged lung cancer. PLoS ONE 2013; 8; e56010.
14. Takeuchi K, Choi YL, Togashi Y et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin. Cancer Res. 2009; 15; 3143-3149.
15. Wong DW, Leung EL, Wong SK et al. A novel KIF5B-ALK variant in nonsmall cell lung cancer. Cancer 2011; 117; 2709-2718.
16. Togashi Y, Soda M, Sakata S et al. KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS ONE 2012; 7; e31323.
17. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363; 1693-1703.
18. Martelli MP, Sozzi G, Hernandez L et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am. J. Pathol. 2009; 174; 661-670.
19. Mino-Kenudson M, Chirieac LR, Law K et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16; 1561-1571.
20. Thunnissen E, Bubendorf L, Dietel M et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012; 461; 245-257.
21. Travis WD, Brambilla E, Konred Müller-Hermelinck H, Harris CC eds. Classification of tumours-pathology and genetics, tumours of lung, pleura, thymus and heart. Lyon: IARC Press, 2004; 42.
22. Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J. Clin. Oncol. 2013; 31; 992-1001.
23. Perner S, Wagner PL, Demichelis F et al. EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 2008; 10; 298-302.
24. Boland JM, Erdogan S, Vasmatzis G et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum. Pathol. 2009; 40; 1152-1158.
25. Ying J, Guo L, Qiu T et al. Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma. Ann. Oncol. 2013; 24; 2589-2593.
26. Lindeman NI, Cagle PT, Beasley MB et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn. 2013; 15; 415-453.
27. Sholl LM, Weremowicz S, Gray SW et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J. Thorac. Oncol. 2013; 8; 322-328.
28. Marchetti A, Ardizzoni A, Papotti M et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J. Thorac. Oncol. 2013; 8; 352-358.
29. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 2012; 30; 863-870.
30. Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers. Med. 2012; 5; 113-123.
31. Zhang YG, Jin ML, Li L et al. Evaluation of ALK rearrangement in Chinese non-small cell lung cancer using FISH, immunohistochemistry, and real-time quantitative RT-PCR on paraffin-embedded tissues. PLoS ONE 2013; 8; e64821.
32. Mikami Y, Ueno T, Yoshimura K et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci. 2013; 104; 1539-1543.
33. Selinger CI, Rogers TM, Russell PA et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod. Pathol. 2013; 26; 1545-1553.
34. To KF, Tong JH, Yeung KS et al. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant. J. Thorac. Oncol. 2013; 8; 883-891.
35. Savic S, Bode B, Diebold J et al. Detection of ALK-positive non-small-cell lung cancers on cytological specimens: high accuracy of immunocytochemistry with the 5a4 clone. J. Thorac. Oncol. 2013; 8; 1004-1011.
36. Yi ES, Boland JM, Maleszewski JJ et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 2011; 6; 459-465.
37. Conklin CM, Craddock KJ, Have C, Laskin J, Couture C, Ionescu DN. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J. Thorac. Oncol. 2013; 8; 45-51.
38. Li Y, Pan Y, Wang R et al. ALK-rearranged lung cancer in Chinese: a comprehensive assessment of clinicopathology, IHC, FISH and RT-PCR. PLoS ONE 2013; 8; e69016.